Subpopulations of cancer stem cells (CSCs) or cancer stem-like cells (CSLCs) have been identified from most tumors, including pancreatic cancer (PC), and the existence of these cells is clinically relevant. Emerging evidence suggests that CSLCs participate in cell growth/proliferation, migration/invasion, metastasis, and chemo-radiotherapy resistance, ultimately contributing to poor clinical outcome. However, the pathogenesis and biological significance of CSLCs in PC has not been well characterized. In the present study, we found that isolated triple-marker-positive (CD44⁺/CD133⁺/EpCAM⁺) cells of human PC MiaPaCa-2 and L3.6pl cells behave as CSLCs. These CSLCs exhibit aggressive behavior, such as increased cell growth, migration, clonogenicity, and self-renewal capacity. The mRNA expression profiling analysis showed that CSLCs (CD44⁺/CD133⁺/EpCAM⁺) exhibit differential expression of more than 1,600 mRNAs, including FoxQ1, compared with the triple-marker-negative (CD44⁻/CD133⁻/EpCAM⁻) cells. The knockdown of FoxQ1 by its siRNA in CSLCs resulted in the inhibition of aggressive behavior, consistent with the inhibition of EpCAM and Snail expression. Mouse xenograft tumor studies showed that CSLCs have a 100-fold higher potential for tumor formation and rapid tumor growth, consistent with over-expression of CSC-associated markers/mediators, including FoxQ1, compared with its parental MiaPaCa-2 cells. The inhibition of FoxQ1 attenuated tumor formation and growth, and expression of CSC markers in the xenograft tumor derived from CSLCs of MiaPaCa-2 cells. These data clearly suggest the role of differentially expressed genes in the regulation of CSLC characteristics, further suggesting that targeting some of these genes could be important for the development of novel therapies for achieving better treatment outcome of PC.

Cancer stem-like cells (CSLCs) reminiscent of cancer stem cells (CSCs) or tumor-initiating cells defined by CD133⁺ were isolated and characterized from the bone marrow of acute myeloid leukemia patients in 1997 (1), which marked the discovery of the role of CSLCs in tumorigenesis and tumor progression. Although CSLCs are similar to normal adult stem cells to some extent, especially their self-renewal and differentiation capacity, CSLCs have unique characteristics, such as their highest capacity of self-renewal, differentiation into multiple cell lineages with greater proliferative potential, prolonged life span, and tumor-initiating potential in vivo (2–4). A large number of studies have shown clear evidence in support of the existence of CSLCs and their clinical implications because the rare subpopulations of CSLCs have been identified from most tumors, such as prostate, lung, breast, pancreas, brain, gastric, and colorectal tumors. These CSLCs are involved in cell growth, migration/invasion, and apoptosis resistance, attributing to treatment resistance and metastasis, leading to poor clinical outcome (2–4). However, the pathogenesis of CSLCs during tumorigenesis and tumor progression has not been well documented.

Although significant advances have been made in the fight against cancers, pancreatic cancer (PC) remains one of the most aggressive and lethal malignant diseases in the world, and remains the 4th leading cause of cancer-related death in the United States (5). For example, it was estimated that 45,220 people would be newly diagnosed with PC, and 38,460 patients would die in 2013 (5). Due to the lack of specific signs and symptoms and the lack of early detection techniques for PC, the majority of patients are diagnosed at an advanced stage (~80% of newly diagnosed cases). The conventional treatments, including surgical resections and chemo-radiotherapy are not effective, which is in part due to therapeutic resistance and greater potential for locally advanced and metastatic disease. The majority of patients will die within an average of 5–6 months after diagnosis. The overall 5-year disease-free survival
rate is 1–4%. It has been reported that very small subpopulations of CSCs (CSCs), positive for CD133, can be identified from PC tissues (6). These CSCs exhibit more aggressive phenotypes, such as increased tumorigenic and metastatic potentials in vitro and in vivo, respectively (6, 7). Therefore, the discovery, mechanistic understanding, and targeting approach for killing of CSCs could open newer avenues for the treatment and/or prevention of tumor aggressiveness for PC.

In the present study, we isolated and characterized CD44+/CD133+/EpCAM+ (triple-marker-positive) cells from human PC cells (MiaPaCa-2 and L3.6pl cells) as the CSCs. These CSCs (triple-marker-positive cells) display aggressive behavior, such as enhanced cell growth, clonogenicity, cell migration, and CSC self-renewal capacity, which was consistent with increased expression of CSC signatures/mediators, compared with cells that are triple-marker-negative. The gene expression profiling analysis showed that CSCs (triple-marker-positive cells) of MiaPaCa-2 cells display differential expressions of more than 1,600 genes, including Bmi1, BMP4, BST2, BTG1, FOPR1, FoxQ1, PRKAR1A, Sox9, TACSTD2, and Wnt3a. The knockdown of FoxQ1 by its siRNA led to attenuate aggressiveness and CSC characteristics, which was consistent with inhibition of EpCAM and snail expression. In vivo studies using a mouse xenograft tumor model showed that CSCs derived from MiaPaCa-2 cells display a 100-fold higher potential for tumor formation and also faster tumor growth, which was consistent with overexpression of CSC-associated markers/mediators, including FoxQ1, compared with its parental cells. The inhibition of FoxQ1 by its siRNA attenuated tumor formation and growth, consistent with the down-regulation of CSC markers/mediators in xenograft tumor derived from CSCs of MiaPaCa-2 cells. Our observation suggests that pathways that are activated in CSCs could be targeted as novel therapies for PC.

**MATERIALS AND METHODS**

**Cell Lines and Culture Conditions—**CD44+/CD133+/EpCAM+ (triple-marker-positive cells) were isolated as the CSCs from human pancreatic cancer cell line MiaPaCa-2 and L3.6pl cells by the fluorescence-activated cell sorting (FACS) technique and cultured in the serum-free sphere formation medium (1:1 DMEM/F-12K medium plus B27 and N2 supplements, Invitrogen) to maintain its undifferentiated status. Moreover, triple-marker-negative (CD44/H11001/EpCAM/H11002) cells from MiaPaCa-2 and L3.6pl cells by the fluorescence-activated cell sorting (FACS) were isolated from MiaPaCa-2 and L3.6pl cells by the fluorescence-activated cell sorting (FACS) technique and cultured in the serum-free sphere formation medium (1:1 DMEM/F-12K medium plus B27 and N2 supplements, Invitrogen) to maintain its undifferentiated status. Moreover, triple-marker-negative (CD44+/CD133+/EpCAM+) cells were isolated from MiaPaCa-2 and L3.6pl cells by the FACS technique and were also cultured in 5% fetal bovine serum (FBS)-DMEM at 37°C in standard culture conditions, as described previously (8, 9). CD44+, CD133+, and EpCAM+ are known as stem cell surface proteins, which have been considered as the pancreatic CSC (CSC) markers (3, 6, 10).

**Sphere Formation Assay—**The sphere formation assay was conducted to assess the CSC self-renewal capacity, as described previously (8, 9). Briefly, 1,000 single suspended cells were seeded on the ultralow attachment wells of Costar 6-well plates (Corning Inc.) in 2 ml of sphere formation medium. After 7 days of incubation, the sphere cells termed “pancreatospheres” were harvested by centrifugation (300 × g for 5 min). The number of pancreatospheres was counted under a converted microscope.

**Colony Formation Assay—**The colony formation assay was conducted to assess clonogenic potential of the cells, as described previously (8, 11). Briefly, 1,000 single viable cells were seeded in 10 ml of 5% FBS-DMEM in 10-cm Petri dishes. The cells were then incubated at 37°C in a tissue culture incubator for 14 days. Colonies were stained with 2% crystal violet, washed with water, and counted.

**Wound Healing Assay—**The wound healing assay was conducted to assess the migration capacity of the cells under different experimental conditions, as described previously (8, 11). The cells were seeded in the 6-well plates in 3 ml of 5% FBS-DMEM medium in each well. When the confluence of the cells grew to 95% or above, they were then scratched with a 200-μl pipette tip. The wound healing capacity was assessed and photographed with a camera-equipped inverted microscope after 20 and 48 h of incubation.

**Cell Cycle Analysis—**A propidium iodide (PI) staining/flow cytometric assay was conducted to assess the cell cycle under different experimental conditions. After washing, the cells were fixed with 4 ml of 75% ethanol at −20°C overnight. The fixed cells were washed and stained with PI-RNase A solution (Invitrogen) at 4°C for 3 h, followed by a standard flow cytometric assay.

**Annexin V/PI Staining and Flow Cytometry Assay—**The annexin V/PI staining and flow cytometry assay was performed to evaluate apoptosis in the cells by using the FITC annexin V apoptosis detection kit (BD Pharmingen), following the manufacturer’s instructions.

**Quantitative Real-time RT-PCR of mRNAs—**The mRNA levels of the cells were measured by the real-time RT-PCR assay, as described previously (8, 11). Total RNAs were isolated by using TRIzol solution (Invitrogen). Reverse transcription (RT) reactions of mRNAs were then conducted by using the High Capacity RNA-to-cDNA assay kit (Applied Biosystems), following the manufacturer’s instructions. RT-PCRs of mRNAs were conducted by using the CYBR Green PCR Master Mix kit (Applied Biosystems). The primers of specific cDNAs were synthesized from Invitrogen. The C values were used for data analysis. GAPDH mRNA was used as the control to normalize the data of mRNAs in each sample.

**Immunostaining and Confocal Imaging Microscopy—**The protein expressions in the cells were assessed by an immunostaining/confocal imaging microscopic assay. After the cells reached 50–70% confluence on the 4-chamber culture glass slides in 0.5 ml of 5% FBS-DMEM, the cells were then harvested, washed, fixed with 4% formaldehyde PBS solution, and permeabilized with 0.05% Tween 20 solution. Antibodies against CD44, EpCAM, Notch-1, EZH2, and Snail (Cell Signaling) were applied for immunostaining, following the manufacturer’s protocol. DAPI solution (Invitrogen) was used to stain the nucleus of the cells as the control. The antibody-labeled cells were examined and photographed.
under a confocal imaging microscope (EVOS Imaging Systems, ×100 magnifications).

Western Blot Analysis—The relative levels of proteins in the cells/tumor tissues were measured by Western blot analysis, as described previously (9). The protein lysis of the samples was prepared as described previously (9). The antibodies against EpCAM, EZH2, Notch-1, Snail, p65, phospho-Akt, and hypoxia-inducible factor-1α were obtained from Cell Signaling Technology. The antibodies against FoxQ1, IL-6, VEGF, and Bmi1 were obtained from Santa Cruz Biotechnology. The antibody against β-actin was obtained from Sigma.

The Gene Expression Profiling—The mRNA microarray assay was conducted for gene expression profiling analysis. Briefly, purified total RNAs were isolated by using the Vana mRNA isolation kit (Ambion Inc., Austin, TX), following the manufacturer’s instructions. Total RNA quantity and quality was examined by analysis using NanoDrop and the Agilent Bioanalyzer (Agilent Technologies). All of the RNA samples had RNA Integrity Number (RIN) scores of ≥7. The whole genome expression profiling was analyzed by a two-color microarray-based approach. The RNA samples were hybridized to Agilent 4 × 44k human arrays and scanned with the Agilent G2505B scanner system. All of the data were analyzed by Agilent Feature Extraction software that generated expression data parameters, including LogRatio p values, LogRatio error, and p value LogRatio. The features included in further analysis were annotated, and gene level passed a p value LogRatio cut-off of ≤0.001. Analysis of variance and multiple test correction (Benjamini-Hochberg p ≤ 0.05) was conducted using Partek software to compare the two sets of four two-color arrayed repli-
cates for the identification of the gene expression level changes (≥2-fold changes).

*Transfections of FoxQ1 siRNA*—FoxQ1 siRNA (Applied Biosystems) was transfected into the CSLCs (triplet-marker-positive cells) by using the DharmaFECT transfection reagent (Thermo Scientific) following the manufacturer’s instructions, as described previously (8, 11). The scrambled siRNA (negative control 2, Applied Biosystems) was used as the negative control. The transfected cells were used for either the sphere formation assay, wound healing assay, or real-time RT-PCR assay as described above.

**Animal Experiment**—The protocol for the animal experiment was approved by the Animal Investigation Committee of Wayne State University. Four-week-old CB17 severe combined immunodeficient (SCID) mice were obtained from Taconic Farms and maintained by feeding regular animal diets (Lab Diet 5021 (Purina Mills, Inc.)), 2 × 10^6 MiaPaCa-2 cells or 2 × 10^4 CSLC triple-marker-positive cells (pancreatosphere cells) under different conditions (control and FoxQ1 siRNA treatment) were implanted as described previously (9). The transfection of siRNAs was described as above. The tumor formation and growth were monitored every other day. After 34 days of inoculation, all of the animals were sacrificed, and tumor tissues from all of the animals were collected for further analysis, such as RT-PCR, Western blot analysis, and histological examination.

**Immunohistochemistry**—Fresh tumor tissues were fixed with zinc formalin solution (Thermo Scientific) overnight and evaluated by hematoxylin and eosin staining, and Immunohistochemistry was performed by a licensed laboratory technician in the Core Facility of the Department of Pathology, Wayne State University.

**TABLE 1**

Apoptosis of the CSLC triple-marker-positive cells versus the triple-marker-negative cells derived from MiaPaCa-2 cells

|                      | Triple-marker-negative cells (n = 3) | CSLC triple-marker-positive cells (n = 3) | p value |
|----------------------|--------------------------------------|------------------------------------------|---------|
| Alive (%)            | 50.60 ± 1.85                         | 59.43 ± 0.40                             | 0.003   |
| Early apoptotic (%)  | 22.47 ± 2.50                         | 12.17 ± 0.63                             | 0.004   |
| Late apoptotic (%)   | 14.03 ± 1.35                         | 22.50 ± 0.30                             | 0.001   |
| Non-apoptotic dead (%) | 12.93 ± 1.86                        | 5.91 ± 1.08                              | 0.009   |

**TABLE 2**

Cell cycles of CSLC triple-marker-positive cells versus triple-marker-negative cells

|                      | Triple-marker-negative cells (n = 3) | CSLC triple-marker-positive cells (n = 3) | p value |
|----------------------|--------------------------------------|------------------------------------------|---------|
| G1 (%)               | 84.50 ± 2.70                         | 73.67 ± 1.12                             | 0.0002  |
| G2 (%)               | 4.74 ± 2.11                         | 8.98 ± 2.30                              | 0.0174  |
| S phase (%)          | 10.77 ± 4.80                        | 17.35 ± 3.32                             | 0.0325  |
Deregulated Expression of Genes in Cancer Stem-like Cells

University/Karmanos Cancer Institute, as described previously (9). The antibodies against CD44, EpCAM, Notch-1, and EZH2 were obtained from Cell Signaling Technology. The stained slides were examined by a licensed pathologist in the Department of Pathology, Wayne State University/Karmanos Cancer Institute.

Statistical Analysis—The data were prepared and presented as mean and S.D. by using GraphPad Prism and Excel software. Student’s t test was performed to test significant difference between two groups. The p value equal or less than 0.05 was considered as statistically significant.

RESULTS

Isolations of CSLC Triple-marker-positive Cells and Triple-marker-negative Cells—The CSLCs (triple-marker-positive cells) were isolated and established from four CD44+/CD133+/EpCAM+ (triple-marker-positive) cells of human PC MiaPaCa-2 cells by using the FACS technique. The triple-marker-negative cells were also isolated and established from 786,353 CD44+/CD133+/EpCAM− (triple-marker-negative) cells of MiaPaCa-2 cells by the FACS technique. After 4 weeks of incubation in the serum-free sphere formation medium, four isolated CSLCs (triple-marker-positive cells) survived and underwent self-renewal to become more than one million of the cells (Fig. 1A, b and d). However, four isolated triple-marker-negative cells failed to survive and grow (Fig. 1A, a and c). A flow cytometric assay was conducted to assess the percentage of triple-marker-positive cells in each subpopulation of cells. The results showed that only 0.18% of cells were triple-marker-positive (CD44+/CD133+/EpCAM+) in MiaPaCa-2 cells (Fig. 1B). Triple-marker-negative cells contained less than 0.01% triple-marker-positive (CD44+/CD133+/EpCAM+) cells (Fig. 1B). However, the CSLCs contained 56% triple-marker-positive (CD44+/CD133+/EpCAM+) cells (Fig. 1B). These data suggest that the triple-marker-negative and triple-marker-positive cells have stable genotypes.

CSLC Self-renewal Capacity of Triple-marker-positive Cells—The sphere formation assay was conducted to assess the CSLCs self-renewal capacity. The results show that the triple-marker-positive cells had significantly increased numbers of pancreatic stem cells after 7 days of incubation in the serum-free sphere formation medium, compared with triple-marker-negative cells (Fig. 1, A and C). We also examined CSC self-renewal capacity using different triple-marker combined phenotypes of MiaPaCa-2 cells, such as CD44−/CD44−/EpCAM−, CD44+/CD133+/EpCAM−, CD44+/CD133+/EpCAM+, CD44+/CD133−/EpCAM+, and CD44+/CD133+/EpCAM+ cells isolated by the FACS technique. The results showed that CSC triple-marker-positive cells had significantly higher levels of sphere formation, compared with their parental MiaPaCa-2 cells and other phenotypes of triple-marker combinations (Fig. 1D). There was no significant difference in the sphere formation capacity between MiaPaCa-2 cells and triple-marker-negative cells (p > 0.05; n = 3; Fig. 1D). These findings suggest that the CSLCs (triple-marker-positive cells) have a remarkably higher potential of self-renewal, suggesting that triple-marker-positive CSLCs are similar to CSCs.

Cell Growth of CSLCs (Triple-marker-positive Cells)—The MTT assay was conducted to assess the cell growth/proliferation of the CSLCs (triple-marker-positive cells) in 5% FBS/DMEM medium. The results show that the triple-marker-positive cells (CSLCs) had a remarkably increased cell growth capacity after 3 days of incubation, compared with the triple-marker-negative cells (p < 0.05; n = 3) (Fig. 2A). The triple-marker-negative cells exhibited more morphological changes similar to those in apoptotic cells than did the triple-marker-positive cells (Fig. 2B).

Apoptosis of CSLCs (Triple-marker-positive Cells)—The results from the apoptosis assay showed that CSLC triple-marker-positive cells derived from MiaPaCa-2 cells had more
alive and fewer early apoptotic/dead cells, compared with the triple-marker-negative cells cultured in the FBS-free sphere formation medium (Table 1), and CSLCs were able to replicate much faster, compared with the triple-marker-negative cells (Figs. 1 (C and D) and 2B). These findings suggest that CSLCs have increased resistance to apoptosis.

**Cell Cycle Patterns of CSLCs (Triple-marker-positive Cells)**—The PI staining/flow cytometry assay was conducted to assess the cell cycle of the CSLCs (triple-marker-positive cells). The results show that CSLCs (triple-marker-positive cells) had a significantly decreased G1 phase and had increased G2 phase and S phase, compared with triple-marker-negative cells (Table 2). These findings suggest that CSLCs (triple-marker-positive cells) have a different pattern of cell cycle.

**Cell Migration of CSLCs (Triple-marker-positive Cells)**—The wound healing assay was conducted to assess the cell migration capacity of triple-marker-positive cells (CSLCs). The results showed that the triple-marker-positive cells (CSLCs) have a greater wound healing capacity after 20 h and 24 h of incubation in 5% FBS-DMEM, compared with the triple-marker-negative cells.

*FIGURE 4.* A, pathway enrichment analysis of the altered expression of genes in CSLCs (triple-marker-positive cells) of MiaPaCa-2 cells compared with triple-marker-negative cells. B, heat map of selective CSLCs and tumor-associated genes in the triple-marker-positive cells. Microarray of mRNAs was performed by using Agilent 4 × 44K human array chips at least in triplicates. Green, negative-fold changes; red, positive-fold changes, compared with parental MiaPaCa-2 and triple-marker-negative cells.
There was no significant difference in wound healing capacity between MiaPaCa-2 cells and triple-marker-negative cells (Fig. 2E). These data suggest that triple-marker-positive CSLCs have a higher capacity of cell migration.

Clonogenicity of CSLCs (Triple-marker-positive Cells)—The clonogenic potential of the cells was assessed by the colony formation assay. The results showed that the triple-marker-positive cells (CSLCs) had a significantly increased capacity for the formation of colonies in 5% FBS-DMEM, compared with the triple-marker-negative cells (Fig. 2D) \( (p < 0.05; n = 3) \). There was no significant difference in colony formation capacity between MiaPaCa-2 cells and triple-marker-negative cells \( (p > 0.05; n = 3; \text{Fig. 2F}) \). These findings suggest that CSLCs (triple-marker-positive cells) exhibit significantly higher clonogenic potential.

CSLCs (Triple-marker-positive Cells) Exhibit High Expression of CSC Signatures/Markers—The confocal imaging microscopic assay was conducted to examine the protein expression of CSC signatures/markers in the cells. The results show that the CSLCs (triple-marker-positive cells) had increased protein expression of CD44, EpCAM, EZH2, Notch-1, and Snail compared with triple-marker-negative cells (Fig. 3).

### TABLE 3

| GenBank™ ID | Gene symbol | Gene description | Fold change* |
|-------------|-------------|------------------|-------------|
| ILMN_1700915 | Bmi1 | BMI1 polycomb ring finger oncogene | 3.928 |
| ILMN_1740900 | BMP4 | Bone morphogenetic protein 4 | 40.432 |
| ILMN_1723480 | BST2 | Bone marrow stromal cell antigen 2 | 14.311 |
| ILMN_1775743 | BTG1 | B-cell translocation gene 1, anti-proliferative | 8.577 |
| ILMN_1661733 | FOLR1 | Folate receptor 1 (adult) | 3.103 |
| ILMN_1669046 | FoxQ1 | Forkhead box Q1 | 20.781 |
| ILMN_2389590 | PRKAR1A | Protein kinase, cAMP-dependent, regulatory, type I, α | 13.915 |
| ILMN_1815745 | Sox4 | SRY (sex-determining region Y)-box 4 | 3.08 |
| ILMN_1739001 | TACSTD2 | Tumor-associated calcium signal transducer 2 | 37.126 |
| ILMN_1815700 | Wnt3a | Wingless-type MMTV integration site family, member 3A | 2.973 |

* Fold change (log2) was calculated based on the data comparisons of CSLC triple-marker-positive cells versus triple-marker-negative cells.
and EpCAM are known as cancer stem cell surface markers (3, 6, 10). EZH2, Notch-1, and Snail are known to play a key role in tumor development and progression and have been considered as potential CSC-positive markers (3, 12, 13). Our data suggest that the CSLCs (triple-marker-positive cells) have remarkably higher expression of CSC signatures/markers.

**Differential Expression Profiling of mRNAs in CSLCs (Triple-marker-positive Cells)**—Microarray analysis was performed to examine the differential expression of mRNAs in the CSLCs (triple-marker-positive cells), compared with triple-marker-negative cells. 1,653 mRNAs were identified to be differentially expressed in CSLCs (triple-marker-positive) versus triple-marker-negative cells (supplemental Table 1). Among these genes, 753 mRNAs were up-regulated, and 900 mRNAs were down-regulated in the CSLCs (triple-marker-positive cells), compared with triple-marker-negative cells (supplemental Table 1). 1,581 mRNAs were identified to be differentially expressed in CSLCs (triple-marker-positive) versus their parental MiaPaCa-2 cells (data not shown here; see supplemental Table 1). There were 1,216 differentially expressed genes that overlapped between the CSLCs (triple-marker-positive cells) versus triple-marker-negative or MiaPaCa-2 cells (data not shown here; see supplemental Table 1). The pathway enrichment analysis shows that differential expression of selected genes is involved in 21 of the major biological function groups, including cell cycle, polo-like kinase, tight junction, cell-cell junction, insulin-like growth factor-1, PI3K/Akt, ERK/MAPK, and VEGF signaling (Fig. 4A). Fig. 4B and Table 3 show the differential expression of 10 selected genes, such as Bmi1 (polycomb ring finger oncogene), BMP4 (bone morphogenetic protein 4), BST2 (bone marrow stromal cell antigen 2), BTG1 (B-cell translocation gene 1), FOLR1 (folate receptor 1), FoxQ1 (forkhead box Q1), PRKAR1A (protein kinase, cAMP-dependent, regulatory, type I, α), Sox4 (sex-determining region Y-box 4), TACSTD2 (tumor-associated calcium signal transducer 2), and Wnt3a (Wingless-type MMTV integration site family, member 3A).

**Real-time RT-PCR Assay of Selected mRNAs**—We selected 10 differentially expressed mRNAs for validation of mRNA microarray data in the CSLCs (triple-marker-positive cells) compared with triple-marker-negative cells by real-time RT-PCR. The results confirmed that the CSLCs (triple-marker-positive cells) have significantly increased expression of Bmi1, BMP4, BST2, BTG1, FOLR1, FoxQ1, PRKAR1A, Sox4, TACSTD2, and Wnt3a genes, compared with the triple-marker-negative cells (Fig. 5), as shown by the microarray data (Table 3). We also examined the gene expression of CSLCs signature genes and tumor-related markers in the CSLCs (tri-
ple-marker-positive cells) by real-time RT-PCR. The results show that the CSLCs (triple-marker-positive cells) have increased expression of \textit{Nanog}, \textit{Oct4}, \textit{Akt}, \textit{p65}, \textit{PLK} (polo-like kinase), \textit{TGF-\beta} (transforming growth factor-\(\beta\)), \textit{HIF-\(\alpha\)} (hypoxia-inducible factor-1\(\alpha\)), \textit{VEGF}, \textit{IL-6} (interleukin-6), and \textit{IGF-1} (insulin-like growth factor-1), compared with triple-marker-negative cells (Fig. 6).

The Expression of CSC-associated Proteins in CSLCs—The results from confocal image microscopy and Western blot analysis showed that CSLC triple-marker-positive cells derived from MiaPaCa-2 cells have remarkably higher expression of phospho-\textit{Akt}, \textit{Bmi1}, \textit{FOLR1}, \textit{FoxQ1}, hypoxia-inducible factor-1\(\alpha\), \textit{IL-6}, \textit{VEGF}, \textit{Oct4}, \textit{EZH2}, \textit{Notch-1}, \textit{EpCAM}, \textit{p65}, and \textit{Snail}, compared with the triple-marker-negative cells (Fig. 7, A and B).

The Role of FoxQ1 in the Regulation of CSLC Phenotypes and Functions in Triple-marker-positive Cells—The altered expression of FoxQ1 has been reported to correlate with poorer clinical prognosis of various tumors (14–16). The evidence from \textit{in vitro} and \textit{in vivo} experimental studies suggests that FoxQ1 may play an important role in tumorigenesis and tumor development by the regulation of various oncogenic signaling pathways (14–16). In the present study, the CSLCs (triple-marker-positive cells) of MiaPaCa-2 cells showed higher expression of FoxQ1, compared with triple-marker-negative cells, as described earlier (Figs. 4B, 5, and 7). To explore the potential role of FoxQ1 in the regulation of CSLC phenotypes and functions, we conducted the functional loss of expression study of FoxQ1 by transfection of its siRNA into the CSLCs (triple-marker-positive cells). The results show that the transfection of FoxQ1 siRNA significantly decreased the mRNA and protein levels of FoxQ1 in the CSLCs (Fig. 8, A and B). The knockdown of FoxQ1 decreased the relative mRNA and protein levels of EpCAM and Snail in these cells (Fig. 8, A and B). The knockdown of FoxQ1 also resulted in a significant decrease in the formation of pancreatospheres and wound healing capacity of these cells (Fig. 8, C and D). Similarly, CSLC triple-marker-positive cells isolated from another human pancreatic cancer L3.6pl cells by FACS technique have also displayed aggressive phenotypes, such as overexpression of FoxQ1, EpCAM, and Snail, as well as increased capacity of CSC self-renewal and higher potential of cell migration, compared with the triple-marker-negative cells derived from L3.6pl cells (Fig. 9). The knockdown of FoxQ1 by its siRNA inhibited these aggressive phenotypes (Fig. 9), which were observed in CSLCs derived from MiaPaCa-2 cells. These findings clearly suggest that FoxQ1 may play an important role in the regulation of CSLC phenotypes and functions, and thus targeting FoxQ1 could become a novel therapeutic approach for PC.

Tumor Formation and Growth in Mouse Xenograft Tumor Models—Mouse xenograft tumor studies showed that the implantation of \(2 \times 10^4\) CSLSs (pancreatosphere cells) has a 100-fold higher potential for tumor formation, compared with the implantation of \(2 \times 10^6\) of their parental MiaPaCa-2 cells (Table 4). CSLCs have also displayed rapid growth in the xenograft tumor model after 34 days of inoculation (874.8 ± 504.4 mg versus 333.5 ± 163.6 mg, comparing CSLCs versus MiaPaCa-2 cells; Table 4). The underexpression of FoxQ1 by its siRNA attenuated tumor formation and growth (Table 4). The histological study showed that xenograft tumors derived from CSLCs displayed more necrosis and a dedifferentiated state and...
also had higher expression of Ki-67 (tumor proliferation index) and CSC-associated proteins, such as FoxQ1, CD44, EpCAM, EZH2, Notch-1, and Snail, compared with xenograft tumor derived from their parental MiaPaCa-2 cells (Fig. 10, A and B). The knockdown of FoxQ1 decreased the expression of CSC markers, such as EpCAM and EZH2, in xenograft tumor derived from CSLCs (Fig. 10, C and D). These findings suggest that CSLCs have very high potential of tumor formation and growth, consistent with overexpression of CSC markers/mediators, including FoxQ1, in vivo. The inhibition of FoxQ1 expression attenuated tumor formation and growth, consistent with the down-regulation of CSC markers/mediators, such as EpCAM and EZH2, in vivo.

FIGURE 8. The effect of knockdown of FoxQ1 on EpCAM and Snail mRNAs (A) and proteins (B), CSLC self-renewal capacity (C), and clonogenicity (D) of triple-marker-positive cells derived from MiaPaCa-2 cells. The transfection of FoxQ1 siRNA was performed in CSLCs (triple-marker-positive cells). Real-time RT-PCR was performed to measure FoxQ1, EpCAM, and Snail mRNAs in triple-marker-positive cells. Confocal imaging microscopy was performed to evaluate the protein expression. DAPI was used to stain the nucleus of the cells. Magnification, ×100. Sphere formation and wound healing assays were performed to evaluate the self-renewal and cell migration capacities of CSLCs, respectively. Error bars, S.D. *, p < 0.05 (n = 3).

DISCUSSION

It has now been well accepted that CSCs (CSLCs) play a critical role during tumorigenesis and tumor progression because the existence of CSLCs has significant clinical implications. The rare population of CSLCs (<0.1%) has been found in many different tumors, including pancreatic cancer (PC), and is related to the poorer clinical outcomes, such as reduced disease-free survival rate and increased mortality (6). Different from tumor non-CSLCs, this minority fraction of CSLC subpopulations exhibits distinct features, such as the highest capacity of self-renewal, prolonged survival potential, and greater capacity of differentiation into multiple different cell types of tumor cells or tumor-associated cells. Emerging evidence suggests that these features are believed to be associated with increased cell growth/proliferation, cell migration/invasion, treatment resistance, and metastasis, leading to poor clinical outcome in most tumors, including PC (17). In the present study, we found that CD44+/CD133+/EpCAM+ cells (triple-marker-positive cells) of pancreatic cancer cells behave like CSCs (CSLCs). These CSLCs that are characterized as triple-marker-positive cells have aggressive phenotypes and functions, which is consistent with overexpression of CSC signa-
Therefore, understanding and targeted killing of these CSLCs would provide a newly effective therapeutic approach for the treatment of aggressive tumors, including PC. However, the regulation of CSLC characteristics during tumorigenesis and tumor progression has not been clearly elucidated. Therefore, further characterization of CSLCs may lead to the discovery of genes that could be targeted for therapy, as discussed below.

In our study, we found overexpression of FoxQ1 (forkhead box Q1) in CSLCs, which is a member of the forkhead transcription factor family known to be critically involved in the regulation of gene expression during different biological processes, such as early development, metabolism, and immune function. Emerging evidence suggests that FoxQ1 may have an important function during tumorigenesis and tumor progression mediated by deregulation of several signaling pathways.

**TABLE 4**

Characteristics of mouse xenograft tumors derived from parental and CSLC triple-marker-positive cells derived from MiaPaCa-2 cells

| Cell numbers of inoculation per animal | Tumor incidence (5 animals/group) | Tumor weight (mean ± S.D.) | p value |
|--------------------------------------|----------------------------------|---------------------------|---------|
| Parental MiaPaCa-2, siRNA control    | 2 × 10^6                         | 4/5                       | 333.5 ± 163.6 | <0.05^a |
| Parental MiaPaCa-2, FoxQ1 siRNA     | 2 × 10^6                         | 0/5                       | 0.0 ± 0.0   |        |
| CSLC, siRNA control                  | 2 × 10^4                         | 4/5                       | 874.8 ± 504.4 |      |
| CSLC, FoxQ1 siRNA                    | 2 × 10^4                         | 1/5                       | 126 ± 0.0   | <0.05^b |

^a,b p values less than 0.05 of the CSLC control group, compared with the MiaPaCa-2 control group and CSLC FoxQ1 siRNA group, respectively.
such as epithelial-to-mesenchymal transition (EMT), a biological process known to be associated with drug resistance and metastasis and also known to be linked with CSLC characteristics (3, 12, 13). Recent clinical studies have shown high levels of FoxQ1 expression in gastric cancer, colorectal cancer, and non-small cell lung cancer (14–16). Moreover, several in vitro and in vitro experimental studies have shown that FoxQ1 expression increases cell growth/proliferation, migration/invasion, angiogenesis, tumorigenicity, and metastasis, which was found to be mediated by the up-regulation of NRXN3 (neurexin 3, a tumor prognostic marker), ZEB1/2, VEGF, Wnt, and BCL in different tumor cells, such as breast, liver, glioma, colorectal, and ovarian cancers (16, 18–20). In addition, the expression of FoxQ1 is regulated by TGF-β/H9252 (20), which suggests that TGF-β-mediated overexpression of FoxQ1 may lead to the acquisition of EMT, a process that is reminiscent of CSC (CSLC) characteristics. The blockage of FoxQ1 by its siRNA inhibitor has been found to inhibit cell invasion and metastasis in vitro through the reversal of EMT in bladder cancer cells (21). However, the role of FoxQ1 in the regulation of CSC (CSLC) phenotypes and functions during tumorigenesis and tumor progression has not been clearly elucidated. In our current study, we demonstrate, for the first time, that higher expression of FoxQ1 is associated with CSLCs signatures/markers and functions in triple-marker-positive cells (CSLCs) isolated from pancreatic cancer cells. The knockdown of FoxQ1 by its siRNA inhibitor resulted in the attenuation of aggressive CSLC phenotypes, consistent with the inhibition in the expression of EpCAM in triple-marker-positive cells (CSLCs) in vivo and in vitro. These data clearly suggest that FoxQ1 plays a key role in the regulation of CSLC phenotypes and functions.

We also found overexpression of bone morphogenetic proteins, such as BMP4, which belongs to a class of important extracellular signaling transducer proteins and also belongs to the TGF-β superfamily. This protein has been considered to exhibit a critical role in early development (22). The clinical data showed that the altered expressions of BMP4 in various tumors, including PC, were found to be associated with poor clinical prognosis. Increased numbers of in vitro and in vivo experimental studies have confirmed the evidence that BMP4 plays an important role in tumorigenesis and tumor progression mediated by promoting cell growth/proliferation and migration/invasion via several signaling pathways/networks, including apoptosis and PI3K/Akt, Wnt, hedgehog, and EMT in different cancers, including PC (23, 24). However, there are some controversial reports showing an inhibitory effect of BMP4 on tumor cell growth in vitro and in vivo. Therefore, the biological function of BMP4 appears to be tumor context-dependent. The role of BMP4 in the regulation of CSLC phenotypes and functions has not been molecularly investigated. There are some limited studies that suggest that BMP4 may be involved in the regulation of CSC phenotypes and functions. For example, BMP4 could decrease cell growth and proliferation in CSC-like CD133+ cells of glioblastoma in vitro and in vivo (25). Moreover, experimental studies have shown that BMP4 can up-regulate the proliferation of human adipose-de-
Deregulated Expression of Genes in Cancer Stem-like Cells

Rivelled stem cells and maintain its stem cell phenotypes and functions in an autocrine and dose-dependent fashion (25–27). It has also been noted that Lin-28 and Oct4, known stem cell factors, work together to up-regulate the expression of BMP4 at the post-transcriptional level, which contributes to the modulation of the ovarian tumor microenvironment (28). In our present study, we found that CSLCs (triple-marker-positive cells) exhibit aggressive tumor cell phenotypes and functions, which was consistent with overexpression of BMP4 and other stem cell markers, suggesting that BMP4 may have an important role in the regulation of CSC (CSLC) characteristics. However, further mechanistic studies are needed for determining the role of BMP4 in CSLCs of PC.

Studies have shown that folate receptor α (FOLR1) could be one such target because FOLR1 is known as a cell surface glycoprotein that regulates the transport of folic acid into the cells. It is well known that the metabolism of folate/folate receptor α plays a critical role in the early development. In most normal adult tissues, FOLR1 is present at a very low level or undetectable; however, increasing amounts of clinical data suggest that FOLR1 is highly expressed in many different tumors, such as lung, ovarian, uterine, colorectal, and pituitary tumors (29–33), which has been shown to be highly associated with poor clinical outcome, such as decreased disease-free survival and increased chemotherapy resistance (29), a feature that is the hallmark of CSLCs (CSCs). Experimental studies have shown that the blockage of folate receptor α by its monoclonal antibody led to the inhibition of human ovarian tumor cell growth in vitro and in vivo (31), suggesting the critical role of FOLR1 in the maintenance of tumor aggressiveness. However, the role of FOLR1 in the regulation of CSLC aggressiveness and function is not clear, although FOLR2 has been found to be overexpressed in acute myeloid leukemia blast cell lines and other hematopoietic progenitor cells (34). Therefore, our triple-marker-positive CSLC model could be a useful model for further investigation with respect to the expression of FOLR1/2 and the cellular consequence of targeting FOLR1/2 in PC.

In summary, our data clearly suggest that the CSLCs (triple-marker-positive; CD44+/CD133+/EpCAM+) exhibit aggressive phenotypes and functions, such as enhanced cell growth, clonogenicity, cell migration, and self-renewal capacity, all of which were consistent with increased expression of CSC (CSLC) signatures/markers. The CSLCs (triple-marker-positive cells) also exhibit differential expression of about 1,600 mRNAs, including Bmi1, BMP4, BST2, BTG1, FOLR1, FoxQ1, PRKAR1A, Sox4, TACSTD2, and Wnt3a, compared with triple-marker-negative cells. The knockdown of FoxQ1 by transfection of its siRNA inhibitor reduced clonogenicity, cell migration, and self-renewal capacity, which was also consistent with the inhibition of CSC (CSLC) signatures/markers, such as EpCAM and Snail, in the CSLCs (triple-marker-positive cells). Mouse xenograft tumor models indicate that CSLCs have a significantly higher potential for tumor formation and faster tumor growth, consistent with overexpression of CSC-associated markers/mediators, including FoxQ1. The inhibition of FoxQ1 resulted in the attenuation of tumor formation and growth and expression of CSC markers in xenograft tumor derived from CSLCs. These findings clearly suggest that differentially expressed mRNAs may play a key role in the regulation of CSC (CSLC) phenotypes and functions, especially through increased expression of Bmi1, BMP4, BST2, BTG1, FOLR1, FoxQ1, PRKAR1A, Sox4, TACSTD2, and Wnt3a.

Note Added in Proof—The online version of this article, published on April 9, 2014, contains an error in Fig. 1B. The top panel labeled “CSLC triple positive” was duplicated and used in place of the correct “Triple negative” panel. The correct “Triple negative” panel appears in the final version of this article. This change does not affect the interpretation of the results or the conclusions.

REFERENCES

1. Bonnet, D., and Dick, J. E. (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730–737
2. Hermann, P. C., Mueller, M. T., and Heeschen, C. (2009) Pancreatic cancer stem cells: insights and perspectives. Expert Opin. Biol. Ther. 9, 1271–1278
3. Li, Y., Kong, D., Ahmad, A., Bao, B., and Sarkar, F. H. (2013) Pancreatic cancer stem cells: emerging target for designing novel therapy. Cancer Lett. 338, 94–100
4. Sarkar, F. H., Li, Y., Wang, Z., and Kong, D. (2009) Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chir. 64, 489–500
5. Siegel, R., Naishadham, D., and Jemal, A. (2013) Cancer statistics, 2013. CA Cancer J. Clin. 63, 11–30
6. Hermann, P. C., Huber, S. L., Herrler, T., Aicher, A., Ellwart, J. W., Guba, M., Bruns, C. J., and Heeschen, C. (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 313–323
7. Li, C., Heidt, D. G., Dalera, P., Burant, C. F., Zhang, L., Adsay, V., Wicha, M., Clarke, M. F., and Simeone, D. M. (2007) Identification of pancreatic cancer stem cells. Cancer Res. 67, 1030–1037
8. Bao, B., Ali, S., Kong, D., Sarkar, S. H., Wang, Z., Banerjee, S., Aboukameel, A., Padhiy, E., Philip, P. A., and Sarkar, F. H. (2011) Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One 6, e17850
9. Bao, B., Ali, S., Banerjee, S., Wang, Z., Logna, F., Azmi, A. S., Kong, D., Ahmad, A., Li, Y., Padhiy, S., and Sarkar, F. H. (2012) Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res. 72, 335–345
10. Yin, S., Li, J., Hu, C., Chen, X., Yao, M., Yan, M., Jiang, G., Ge, C., Xie, H., Fan, D., Wang, D., Yang, S., Zheng, S., and Gu, J. (2007) CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int. J. Cancer 120, 1444–1450
11. Ali, S., Ahmad, A., Banerjee, S., Padhye, S., Dominiaik, K., Schaffert, J. M., Wang, Z., Philip, P. A., and Sarkar, F. H. (2010) Gencitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res. 70, 3606–3617
12. Kong, D., Banerjee, S., Ahmad, A., Li, Y., Wang, Z., Sethi, S., and Sarkar, F. H. (2010) Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One 5, e12445
13. van Vlerken, L. E., Kiefer, C. M., Morehouse, C., Li, Y., Groves, C., Wilson, S. D., Yao, Y., Hollingsworth, R. E., and Hurt, E. M. (2013) EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter. Stem Cells Transl. Med. 2, 43–52
14. Feng, J., Zhang, X., Zhu, H., Wang, X., Ni, S., and Huang, J. (2012) FoxQ1 overexpression influences poor prognosis in non-small cell lung cancer, associates with the phenomenon of EMT. PLoS One 7, e9937
15. Liang, S. H., Yan, X. Z., Wang, B. L., Jin, H. F., Yao, L. P., Li, Y. N., Chen, M., Nie, Y. Z., Wang, X., Guo, X. G., Wu, K. C., Ding, J., and Fan, D. M. (2013) Increased expression of FOXQ1 is a prognostic marker for patients with gastric cancer. Tumour Biol. 34, 2605–2609
16. Kaneda, H., Arao, T., Tanaka, K., Tamura, D., Aomatsu, K., Kudo, K.,...
17. Hermann, P. C., Bhaskar, S., Cioffi, M., and Heeschen, C. (2010) Cancer stem cells in solid tumors. *Semin. Cancer Biol.* **20**, 77–84

18. Sun, H. T., Cheng, S. X., Tu, Y., Li, X. H., and Zhang, S. (2013) FoxQ1 promotes glioma cells proliferation and migration by regulating NRXN3 expression. *PLoS One* **8**, e55693

19. Xia, L., Huang, W., Tian, D., Zhang, L., Qi, X., Chen, Z., Shang, X., Nie, Y., and Wu, K. (2014) FoxQ1 promotes hepatocellular carcinoma metastasis by trans-activating ZEB2 and VersicanV1 expression. *Hepatology* **59**, 958–973

20. Zhang, H., Meng, F., Liu, G., Zhang, B., Zhu, J., Wu, F., Ethier, S. P., Miller, F., and Wu, G. (2011) Forkhead transcription factor foxq1 promotes epithelial-mesenchymal transition and breast cancer metastasis. *Cancer Res.* **71**, 1292–1301

21. Zhu, Z., Zhu, Z., Pang, Z., Xing, Y., Wan, F., Lan, D., and Wang, H. (2013) Short hairpin RNA targeting FOXQ1 inhibits invasion and metastasis via the reversal of epithelial-mesenchymal transition in bladder cancer. *Int. J. Oncol.* **42**, 1271–1278

22. Kallioniemi, A. (2012) Bone morphogenetic protein 4: a fascinating regulator of cancer cell behavior. *Cancer Genet.* **205**, 267–277

23. Katoh, Y., and Katoh, M. (2009) Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. *Curr. Mol. Med.* **9**, 873–886

24. Katoh, Y., and Katoh, M. (2006) Hedgehog signaling pathway and gastrointestinal stem cell signaling network (review). *Int. J. Mol. Med.* **18**, 1019–1023

25. Altaner, C. (2008) Glioblastoma and stem cells. *Neoplasma* **55**, 369–374

26. Villageois, P., Wdziekonski, B., Zaragosi, L. E., Plassant, M., Mohsen-Kanson, T., Lay, N., Ladoux, A., Peraldi, P., and Dani, C. (2012) Regulators of human adipose-derived stem cell self-renewal. *Am. J. Stem Cells* **1**, 42–47

27. Vicente López, M. A., Vázquez García, M. N., Entrrena, A., Olmedillas López, S., García-Arranz, M., García-Olmo, D., and Zapata, A. (2011) Low doses of bone morphogenetic protein 4 increase the survival of human adipose-derived stem cells maintaining their stemness and multipotency. *Stem Cells Dev.* **20**, 1011–1019

28. Ma, W., Ma, J., Xu, J., Qiao, C., Branscum, A., Cardenas, A., Baron, A. T., Schwartz, P., Maibohm, N. L., and Huang, Y. (2013) Lin28 regulates BMP4 and functions with Oct4 to affect ovarian tumor microenvironment. *Cell Cycle* **12**, 88–97

29. Allard, J. E., Risinger, J. I., Morrison, C., Young, G., Rose, G. S., Fowler, J., Berchuck, A., and Maxwell, G. L. (2007) Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas. *Gynecol. Oncol.* **107**, 52–57

30. D’Angelica, M., Ammori, J., Klimstra, D. S., Low, P. S., Murphy, L., Weiser, M. R., Paty, P. B., Fong, Y., Dematteo, R. P., Allen, P., Jarnagin, W. R., and Shia, J. (2011) Folate receptor-α expression in resectable hepatic colorectal cancer metastases: patterns and significance. *Mod. Pathol.* **24**, 1221–1228

31. Ebel, W., Routhier, E. L., Foley, B., Jacob, S., McDonough, J. M., Patel, R. K., Turchin, H. A., Chao, Q., Kline, J. B., Old, L. J., Phillips, M. D., Nicolaides, N. C., Sass, P. M., and Grasso, L. (2007) Preclinical evaluation of MORAB-003, a humanized monoclonal antibody antagonizing folate receptor-α. *Cancer Immun.* **7**, 6

32. Toffoli, G., Russo, A., Gallo, A., Cernigoi, C., Miotti, S., Sorio, R., Tumolo, S., and Boiocchi, M. (1998) Expression of folate-binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. *Int. J. Cancer* **79**, 121–126

33. Wood, L. D. (2012) Folate receptor-α: a new tool in the diagnosis and treatment of lung cancer. *Oncotarget* **3**, 668–669

34. Clarhaut, J., Fraineau, S., Guilhot, J., Peraudeau, J., Tranoy-Opalinski, I., Thomas, M., Renoux, B., Randriamalala, E., Bois, P., Chatelier, A., Monvoisin, A., Cronier, L., Papot, S., and Guilhot, F. (2013) A galactosidase-responsive doxorubicin-folate conjugate for selective targeting of acute myelogenous leukemia blasts. *Leuk. Res.* **37**, 948–955